About MS  > MS news and research  > Drugs  > laquinimod
About MS

What is MS?

MS symptoms

Managing your MS

Effects of MS

MS news and research

Alternative medicine

Bacteria and viruses

Biomarkers and microRNA

Brain inflammation, lesions & 'black holes'

Cancer and MS

CCSVI

Cognition

Diet

Drugs

Ampyra (Fampyra)

ATL1102

Aubagio

Cannabis and cannabinoids

Copaxone and glatiramer acetate

Emerging therapies

Gilenya

Low dose naltrexone

Lemtrada (alemtuzumab)

Masitinib

MIS416

MN-166 (ibudilast)

Nerventra® (laquinimod)

Plegridy (peginterferon beta-1a)

Rebif

Rituximab (rituxan)

RPC1063

Sativex

Statins

Tecfidera

Trimesta (oral estriol)

Tysabri

Zenapax (daclizumab)

Endo-parasites and helpful organisms

Environmental factors

Ethnic groups, geographical regions and MS

Exercise

Gender and MS

Genetics

Hormones

Immune cells

Lipids

Medical imaging

MS Symptoms research

Multiple Sclerosis (etiology)

Myelin

Nerves, brain cells and spinal cord

Paediatric MS

Pain

Quality of life

Retroviruses

Sex and MS

Stem cells

Technology

Types of MS

Vaccinations

Vitamin D

World MS Day

News and research archive

Other support

Donate with JustGiving

Latest Tweets

Nerventra® (laquinimod)

Laquinimod

 

 

 

 

 

 

 

Teva and Active Biotech to continue with the development of Nerventra(R) (laquinimod) for multiple sclerosis(27/05/14)

Teva Pharmaceutical Industries Ltd. and Active Biotech announced that the Committee for Medicinal Products for Human Use's (CHMP) confirmed its January 23, 2014 opinion to recommend against approval for the treatment of relapsing-remitting multiple sclerosis (RRMS) in the European Union (EU) at this time.

Both companies remain committed to the Nerventra(R) (laquinimod) clinical development program for multiple sclerosis (MS) and are focused on evaluating the CHMP feedback to determine potential next steps.

"We are disappointed with the outcome of the re-examination and will be working with the EMA to make Nerventra available to multiple sclerosis patients in the EU," said Michael Hayden, President of Global R&D and Chief Scientific Officer. "We believe Nerventra has a favorable risk-benefit profile and the potential to fulfill an unmet need for a treatment that decreases disability progression, and protects against brain volume loss, two important goals in the management of MS."

To further confirm the benefits of Nerventra on disability progression, Teva is conducting the CONCERTO trial, the largest MS trial with disability progression as the primary endpoint. The ongoing CONCERTO trial is the third Phase III study in RRMS and explores daily doses of Nerventra 0.6 mg and 1.2 mg. In addition, Teva is investigating the potential of Nerventra in progressive forms of MS. The first trial for this indication is planned to be initiated soon.

About Nerventra(R)

Nerventra is a once-daily oral, investigational, CNS-active immunomodulator with a novel mechanism of action being developed for the treatment of relapsing-remitting MS (RRMS) and progressive forms of MS. In extensive non-clinical and clinical studies, NERVENTRA has demonstrated both anti-inflammatory and neuroprotective properties and effects that have been shown to provide clinically meaningful results. The global Phase III clinical development program evaluating Nerventra in MS includes two pivotal studies, ALLEGRO and BRAVO. A third Phase III Nerventra trial, CONCERTO, is evaluating two doses of the investigational product (0.6mg and 1.2mg) in approximately 2,100 patients for up to 24 months. The primary outcome measure will be time to confirmed disability progression as measured by the EDSS, making CONCERTO the largest MS clinical trial with disability progression as the primary endpoint.

The safety profile of Nerventra is based on 2,645 MS patients that have been exposed to Nerventra for a total duration of 7,491 subject years, with a maximal duration of seven years. Very common or important adverse reactions include headache, abdominal pain, back and neck pain, appendicitis, and mild, asymptomatic laboratory abnormalities, including liver enzyme elevations, hematological changes, and elevation of CRP or fibrinogen levels.

In addition to the MS clinical studies, studies are planned to evaluate the efficacy, safety and tolerability of Nerventra in other neurodegenerative diseases including Huntington's disease.

Source: Reuters Copyright (C) 2014 Thomson Reuters (27/05/14)

Change in the clinical development program for laquinimod(19/02/14)

Active Biotech today announces that its partner Teva Pharmaceuticals, has decided not to proceed to the randomization stage of the planned Libretto trial for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS), as the current design is no longer aligned with the regulatory strategy. This decision has no impact on other ongoing studies, such as CONCERTO, which are proceeding as planned, or on Teva Pharmaceuticals' plans to initiate clinical studies in Primary Progressive Multiple Sclerosis (PPMS).

About laquinimod (Nerventra(R))

Laquinimod (Nerventra(R)) is an oral, investigational, CNS-active immunomodulator with a novel mechanism of action primarily being developed for the treatment of relapsing-remitting MS (RRMS). The global Phase III clinical development program evaluating oral laquinimod in MS includes two pivotal studies, ALLEGRO and BRAVO. A third Phase III laquinimod trial, CONCERTO, is evaluating two doses of the investigational product (0.6mg and 1.2mg) in approximately 1,800 patients for up to 24 months. The primary outcome measure will be time to confirmed disability progression as measured by the EDSS. In addition to the MS clinical studies, laquinimod has concluded Phase II of development for Crohn's disease and lupus nephritis.

Source: Market Watch Copyright © 2014 MarketWatch, Inc (19/02/14)

CHMP recommends against EU approval of MS drug Nerventra® (Laquinimod)(29/01/14)

The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has recommended against approval of a new drug for multiple sclerosis (MS).

During their monthly meeting on January 23, the CHMP panel adopted a negative opinion on granting marketing authorization for laquinimod ( Nerventra, Teva Pharma) in patients with relapsing-remitting MS.

The panel noted concerns about results from animal studies showing a higher occurrence of cancers after long-term exposure to laquinimod, noting that a similar long-term risk could not be ruled out in humans, "especially when considering that the way the medicine works in the body is unclear," the EMA noted in a press release.

There was also a possible risk from animal data on teratogenic effects in offspring of women taking the drug, the panel said. "The CHMP noted that the risk could not be excluded with current data and that animal studies suggest that any harmful effects may be delayed and only seen later on in the child's life. In addition, the Committee was not convinced about the effectiveness of the company's proposed measures to prevent pregnancies in women who would take the medicine."

The CHMP panel also pointed out that although the drug had been shown to slow the worsening of disability, its effect on relapses was "modest."

The 2 phase 3 trials of laquinimod completed to date were called ALLEGRO (Assessment of Oral Laquinimod in Preventing Progression in Multiple Sclerosis) and BRAVO. Hope was high for this agent after results of ALLEGRO were published in the New England Journal of Medicine, showing laquinimod reduced the annualized relapse rate as well as delayed progression of disability vs placebo.

In BRAVO, however, which compared oral laquinimod with an active comparator, interferon β-1a ( Avonex, Biogen Idec), the trial missed the primary endpoint of a reduction of annualized relapse rates. However, the reduction seen with laquinimod was significant after researchers adjusted for an imbalance in the volume of T2 disease between groups and the number of gadolinium-enhancing lesions on MRI.

Both trials showed a reduction in disability that was unexpected given the effect seen on relapse rates, raising the possibility that the agent might be affecting disability through some novel mechanism. A reduction in brain atrophy was also noted, which was in line with the effect on disability, another novel finding with this agent.

The upshot is that laquinimod is now being evaluated in a third phase 3 trial, CONCERTO, after a Special Protocol Assessment agreement was reached with the US Food and Drug Administration (FDA). The trial will assess 2 doses of laquinimod — 0.6 and 1.2 mg daily for up to 24 months — in about 1800 patients with relapsing-remitting MS. The primary outcome will be confirmed disability progression on the Expanded Disability Status Scale.

For its part, "the CHMP was of the view that the benefits of Nerventra in patients with relapsing-remitting MS do not outweigh the potential risks and recommended that it be refused marketing authorisation," the EMA release notes.

The CHMP opinion has is no consequences "for the time being" on any ongoing trials of laquinimod, it concludes.

Source: Medscape Multispeciality Copyright © 1994-2014 by WebMD LLC (29/01/14)

Development continues on MS drug Nerventra® (laquinimod) following the EMA’s CHMP negative opinion(24/01/14)

Teva Pharmaceutical Industries Ltd and Active Biotech announced today that both companies remain committed to the Nerventra® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

The CHMP has concluded that the risk-benefit profile of Nerventra is not favourable at this time. In accordance with European regulations, Teva and Active Biotech intend to request a re-examination of the CHMP opinion. Teva and Active Biotech are focusing on evaluating the CHMP’s review and will continue to liaise closely with the EMA in working to make Nerventra available as a new treatment option for patients with RRMS in Europe.

ABOUT Nerventra

NERVENTRA is a once-daily oral, investigational, CNS-active immunomodulator with a novel mechanism of action being developed for the treatment of relapsing-remitting MS (RRMS) and progressive MS (PMS). In extensive non-clinical and clinical studies Nerventra has demonstrated both anti-inflammatory and neuroprotective properties and effects that have been shown to provide clinically meaningful results. The global Phase III clinical development program evaluating Nerventra in MS includes two pivotal studies, ALLEGRO and BRAVO. A third Phase III Nerventra trial, CONCERTO, is evaluating two doses of the investigational product (0.6mg and 1.2mg) in approximately 1,800 patients for up to 24 months. The primary outcome measure will be time to confirmed disability progression as measured by the EDSS.

The safety profile of Nerventra is based on 2645 MS patients that have been exposed to Nerventra for a total duration of 7490.8 subject years, with a maximal duration of seven years. Very common or important adverse reactions include headache, abdominal pain, back and neck pain, appendicitis, and mild, asymptomatic laboratory abnormalities, including liver enzyme elevations, hematological changes, and elevation of CRP or fibrinogen levels. Potential risks include teratogenicity and carcinogenicity, both related to findings in rats, which are based on non-clinical data and have not been encountered in patients.

In addition to the MS clinical studies, Nerventra is currently in clinical development for Crohn's disease. Studies are also planned to study the efficacy, safety and tolerability of Nerventra in other neurodegenerative diseases, including Huntington’s disease.

Source: MarketWatch Copyright © 2014 MarketWatch, Inc (24/01/14)

EMA defers decision on MS drug Laquinimod(23/12/13)

The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) decided on Friday to defer a decision on Laquinimod, an oral treatment for relapsing-remitting multiple sclerosis (RRMS). Laquinimod is being developed jointly by Teva Pharmaceutical Industries Ltd, and Swedish company Active Biotech. According to Active Biotech, the EMA will issue an opinion at its January, 2014 meeting.

Press reports overseas state that the EMA spokesperson refused to provide further details, but said that the agency's experts were entitled to decide on a postponement of a decision of this kind if they saw a necessity to do so.

The future of Laquinimod is uncertain, since it failed to achieve the main endpoints in a clinical trial in 2011. The US Food and Drug Administration (FDA) has requested an additional Phase III trial before it will consider the companies' application to approve the product for sale.

Teva hopes that the drug will be launched in Europe in 2014. There are already several orally administered treatments for multiple sclerosis on the market, among them Biogene's Tecfidera, which analysts see becoming a blockbuster drug, with annual sales of $3 billion.

Source: Globes © Globes 2013 (23/12/13)